|
|
|
| Clinical effect of Wuzhi Dripping Pills combined with Entecavir in treatment of chronic hepatitis B |
| HU Jiang-ling XU Fei JIANG Man-lei LUO Jia-yu |
| Department of Hepatology,Ganzhou Fifth People′s Hospital,Jiangxi Province,Ganzhou 341000,China |
|
|
|
| Guide |
|
|
Abstract Objective To observe the clinical effect of Wuzhi Dripping Pills combined with Entecavir in treatment of chronic hepatitis B (CHB).Methods A total of 80 patients with CHB who admitted to Ganzhou Fifth People′s Hospital from December 2015 to December 2019 were selected and divided into two groups according to random number table method,40 cases in each group.The control group was given Entecavir and Interferon,and research group added Wuzhi Dripping Pills.The total effective rate,TCM syndrome score,liver function （alanine transaminase [ALT],aspartic transaminase [AST],γ-glutamyl transpeptidase [GGT]）,and adverse reactions were compared between two groups.Results The total curative effective rate of patients in research group was higher than that in the control group,with statistical difference (P<0.05).The scores of primary symptom and secondary symptom in research group were lower than those in control group after treatment (P<0.05).The levels of ALT,AST and GGT of patients in research group were lower than those in control group after treatment,with statistical differences (P<0.05).There was no statistically significant difference between the two groups in the total incidence of adverse reactions (P＞0.05).Conclusion Wuzhi Dripping Pills combined with Entecavir in treatment of CHB has significant effects it can improve clinical symptoms and liver function,and have higher safety,which is worthy of clinical promotion and application.
|
|
|
|
|
| Fund: |
|
|
|
| [1] |
欧国进，王珏，刘忠.HLA与HBV感染相关性研究进展[J].中国输血杂志，2018，31（11）：1321-1326.
|
| [2] |
王江滨.抗病毒药物与慢性病毒性肝炎[J].中华消化杂志，2019，39（3）：158-161.
|
| [3] |
中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南（2019年版）[J].临床肝胆病杂志，2019，35（12）：2648-2669.
|
| [4] |
郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国中医药科技出版社，2002：115.
|
| [5] |
刁士琦，吴昊.恩替卡韦联合用药在肺结核合并慢性乙肝治疗中的作用及安全性探讨[J].中国药物与临床，2018，18（7）：1208-1209.
|
| [6] |
张婷，郑凤祥，刘杨清.恩替卡韦联合瑞舒伐他汀治疗慢性乙型病毒性肝炎合并高脂血症的效果[J].中国当代医药，2018，25（33）：131-133.
|
| [7] |
张丽翠，钟晨，张砚，等.恩替卡韦治疗慢性乙型病毒性肝炎患者的临床研究[J].中国临床药理学杂志，2019，35（20）：2539-2542.
|
| [8] |
周红，杨凤，王容，等.聚乙二醇干扰素α-2a 联合恩替卡韦治疗CHB 的效果及对肝功能和肝纤维化的影响[J].疑难病杂志，2019，18（7）：682-686.
|
| [9] |
杨慧敏.中医辨治内伤发热验案四则[J].国际中医中药杂志，2018，40（4）：375-376.
|
| [10] |
忻巧娜，王邦才.王邦才教授治疗慢性乙型病毒性肝炎经验浅析[J].浙江中医药大学学报，2016，40（1）：38-40.
|
| [11] |
邵建柱，张婧，郭杏林，等.五味子的临床应用及其用量探究[J].吉林中医药，2019，39（2）：162-164，168.
|
| [12] |
罗运凤，高洁，柴艺汇，等.五味子药理作用及临床应用研究进展[J].贵阳中医学院学报，2019，41（5）：93-96.
|
| [13] |
邱明阳，赵武，刘玉婷，等.五味子抗氧化及抑制α-葡萄糖苷酶活性的比较研究[J].天然产物研究与开发，2018，30（5）：840-846.
|
| [14] |
白文宇，王厚恩，王冰瑶，等.五味子化学成分及其药理作用研究进展[J].中成药，2019，41（9）：2177-2183.
|
| [15] |
余明杰，王萍，韩媛媛，等.肝功能指标及肝纤维化标志物在乙型肝炎患者中的测定意义研究[J].中华医院感染学杂志，2017，27（13）：2912-2915.
|
|
|
|
